United Therapeutics extends credit facility maturity to March 31, 2029

UNITED THERAPEUTICS Corp

Second one-year extension of $1.2B and $800M revolving credit facilities.
New maturity date March 31, 2029; effective March 29, 2024.
Facility capacity can be increased by up to $500M aggregate.
All other terms of the credit agreement remain unchanged.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.4

UNITED THERAPEUTICS Corp entered into Credit Agreement with Wells Fargo Bank, National Association valued at up to $1.2 billion (effective 2022-03-31).

Action: entry
Agreement: credit facility
Counterparty: Wells Fargo Bank, National Association
Value: up to $1.2 billion
Effective: 2022-03-31

Exact text from the filing

on March 31, 2022, United Therapeutics Corporation (the Company ) entered into a Credit Agreement (the Credit Agreement ) with certain of its subsidiaries party thereto, as guarantors, the lenders referred to therein, and Wells Fargo Bank, National Association ( Wells Fargo ), as administrative agent and as a swingline lender.

View on SEC.gov

438 material agreements filed in the last 30 days. Browse all material agreements →

UNITED THERAPEUTICS Corp filing history →

Source: SEC EDGAR

accession 0001104659-24-041160

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.